Finally, we demonstrate the potential expanded utility of DLL3-targeted therapies beyond NENs, finding robust expression of DLL3 in gliomas, medulloblastomas, and melanomas, among other non-neuroendocrine cancer types. This evidence concerns the gene DLL3 and glioma.